Vericel (Vericel) Change In Receivables : $-11.6 Mil (TTM As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Vericel Change In Receivables?

Vericel's change in receivables for the quarter that ended in Mar. 2024 was $8.4 Mil. It means Vericel's Accounts Receivable declined by $8.4 Mil from Dec. 2023 to Mar. 2024 .

Vericel's change in receivables for the fiscal year that ended in Dec. 2023 was $-11.8 Mil. It means Vericel's Accounts Receivable increased by $11.8 Mil from Dec. 2022 to Dec. 2023 .

Vericel's Accounts Receivable for the quarter that ended in Mar. 2024 was $49.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vericel's Days Sales Outstanding for the three months ended in Mar. 2024 was 88.85.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vericel's liquidation value for the three months ended in Mar. 2024 was $32.1 Mil.

Vericel Change In Receivables Historical Data

The historical data trend for Vericel's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Change In Receivables Chart

Vericel Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-8.71

-2.34

-2.93

-9.10

-11.82

Vericel Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															8.18	0.04	-1.41	-18.63	8.42

Vericel Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.6 Mil.

Vericel (NAS:VCEL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vericel's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	49.934	/	51.281	*	91
=	88.85

2. In Ben Graham's calculation of liquidation value, Vericel's accounts receivable are only considered to be worth 75% of book value:

Vericel's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	110.648	-	122.765	+	0.75 * 49.934	+	0.5 * 13.557
=	32.1

Vericel Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vericel's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Vericel (Vericel) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ATQP:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Executives

Dominick Colangelo	director, officer: President and CEO	1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md	director
Paul K Wotton	director	C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn	officer: SVP, General Counsel	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin	officer: Chief Operating Officer	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper	officer: Chief Medical Officer	64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal	officer: Principal Accounting Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright	director	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr	officer: Chief Financial Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell	officer: VP and Corporate Controller	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel	officer: CFO & VP , Corp. Development	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando	officer: Chief Operating Officer	P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino	director	PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp	10 percent owner	1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019